Details
| Original language | English |
|---|---|
| Pages (from-to) | 3300-3303 |
| Number of pages | 4 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 23 |
| Issue number | 11 |
| Early online date | 3 Apr 2013 |
| Publication status | Published - 1 Jun 2013 |
| Externally published | Yes |
Abstract
The p38α mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38α MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38α MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures.
Keywords
- Cardiomyocytes, Differentiation, Human embryonic stem cells, Imidazoles, p38 MAPK
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Molecular Medicine
- Biochemistry, Genetics and Molecular Biology(all)
- Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmaceutical Science
- Pharmacology, Toxicology and Pharmaceutics(all)
- Drug Discovery
- Biochemistry, Genetics and Molecular Biology(all)
- Clinical Biochemistry
- Chemistry(all)
- Organic Chemistry
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 11, 01.06.2013, p. 3300-3303.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells
AU - Low, Joo Leng
AU - Jürjens, Gerrit
AU - Seayad, Jayasree
AU - Seow, Jasmine
AU - Ting, Sherwin
AU - Laco, Filip
AU - Reuveny, Shaul
AU - Oh, Steve
AU - Chai, Christina L.L.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - The p38α mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38α MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38α MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures.
AB - The p38α mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38α MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38α MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures.
KW - Cardiomyocytes
KW - Differentiation
KW - Human embryonic stem cells
KW - Imidazoles
KW - p38 MAPK
UR - http://www.scopus.com/inward/record.url?scp=84877585186&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2013.03.103
DO - 10.1016/j.bmcl.2013.03.103
M3 - Article
C2 - 23602399
AN - SCOPUS:84877585186
VL - 23
SP - 3300
EP - 3303
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
SN - 0960-894X
IS - 11
ER -